{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-014372","form_type":"8-K","ticker":"LMAT","cik":"0001158895","company_name":"LEMAITRE VASCULAR INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.486211+00:00","generated_at":"2026-06-02T23:55:54.956059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeMaitre Vascular Q1 sales $53.5M (+14%), EPS $0.44 (+62%); raises FY op. margin guidance to 22%","bullets":["Q1 net income $9.9M (+64%); gross margin 68.6% (+300 bps) on price increases and manufacturing efficiencies.","Allografts (+31%), carotid shunts (+27%), and APAC sales (+44%) led growth; organic sales +11%.","Board declared $0.16/share dividend payable May 30 to holders of record May 16.","FY 2024 guided sales $212.7-217.3M (+11%), EPS $1.73-1.84 (+33% vs. FY 2023), operating margin 22%.","Share repurchase program of up to $50M authorized through Feb 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-014372","json":"https://secwatch.observer/filing/0001437749-24-014372.json","markdown":"https://secwatch.observer/filing/0001437749-24-014372.md","text":"https://secwatch.observer/filing/0001437749-24-014372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924014372/0001437749-24-014372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924014372/lmat20240502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:55:54.956059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0441bd1db18b879bcffa14a56aeb7b9056385bc0","claim":"LEMAITRE VASCULAR INC reported the quarter ended March 31, 2024 results: revenue $53.5mm, net income $9.9mm, EPS $0.44. Guidance reaffirmed.","evidence_excerpt":"LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results ● Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 ● Gross margin 68.6%, +300 bps ● Op. income $11.9mm, +51% ● Op. margin 22% ● Net income $9.9mm, +64% ● Earnings per diluted share $0.44, +62%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924014372/0001437749-24-014372-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$53.5mm"},{"label":"Net income","value":"$9.9mm"},{"label":"EPS","value":"$0.44"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}